New combo aims to boost immune attack on rare melanoma
NCT ID NCT05089370
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This early-phase trial tests whether adding an oral drug (DEC-C) to the immunotherapy nivolumab can help the immune system better fight advanced mucosal melanoma, a rare and hard-to-treat skin cancer. The study includes 8 adults with unresectable or metastatic disease. The main goals are to check safety and find the best dose, while also measuring tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.